期刊
CANCER TREATMENT REVIEWS
卷 98, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2021.102224
关键词
Ovarian cancer; VEGF; VEGFR inhibitor; PARP inhibitor; Immunotherapy; Combination therapy
类别
资金
- Intramural Research Program of the National Cancer Institute, Center for Cancer Research, NCI, USA [ZIA BC011525]
Ovarian cancer has a variety of treatment options, but achieving sustained benefit in the clinic remains challenging. Biomarker and genetic analysis can identify resistance and sensitivity pathways, providing potential for unique drug combinations.
Ovarian cancer is a deadly malignancy with a growing therapeutic armamentarium, though achieving sustained benefit in the clinic remains largely elusive. Through biomarker and genetic analysis, several pathways of resistance and sensitivity to commonly used therapeutics have been identified, expanding the potential of identifying unique drug combinations and indicating new directions for improving clinical outcomes. Here, we review the mechanisms of angiogenic response and antiangiogenic therapy in ovarian cancer, as well as the interactions it exhibits with the immune and DNA damage response pathways. We discuss results from clinical trials examining the combinations of antiangiogenics, PARP inhibitors, and immune checkpoint inhibitors are also discussed, as well as several ongoing trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据